IMMUCELL CORP /DE/ Q3 FY2024 earnings call

• Production: No contamination since April 2024, with remediation steps implemented to address prior contamination events. Optimizing raw material mix and process parameters to improve yields.
• Sales: Expecting 2024 sales to be higher than 2023 and 2022.
• Re-Tain FDA Approval: Received CMC Technical Section Incomplete Letter, working on fourth submission with FDA, aiming for expedited review after resolving inspectional observations at contract manufacturer's facilities.
• Cash Position: At-the-market offering in 2024 improved cash position from $979,000 on December 31, 2023, to ~$3.8 million on September 30, 2024.
• Product Development: Reducing product development expenses while awaiting Re-Tain approval, exploring strategic partnerships to offset expenses.

Product sales for ImmuCell Corporation increased by 11%, 51%, and 46% during the 3, 9, and 12 month periods ended September 30, 2024, respectively, compared to the same periods in 2023. Gross margin as a percentage of product sales improved from 23% to 26% for the three month period, 21% to 27% for the nine month period, and 22% to 27% for the twelve month period, but remains below the target of 35% to 40%. The main product segment is First Defense, which has strong customer demand but faced challenges due to capacity expansion investments and production contamination issues.

• Expect to increase 2024 sales over 2023 and 2022.
• Aim to improve process yields starting in the fourth quarter of 2024 by optimizing critical process parameters.
• Anticipate Re-Tain resubmission to potentially have a shortened review period if inspectional observations are resolved.

• Risk of production contamination if process parameters and inputs are not properly optimized.
• Inflationary pressures impacting labor and component costs.
• Uncertainty in the FDA review timeline for Re-Tain resubmission due to ongoing inspectional observation issues at the contract manufacturer's facilities.

Q: About the increase in cost of goods sold and gross margin, A: Discussed contamination events leading to write-offs, yield issues, and product mix changes (e.g., shift to Tri-Shield format which is more expensive to produce).

Q: About shares sold and at-the-market offering, A: At-the-market offering contributed to capital needs, improving cash position, and future plans depend on capital needs and stock price.

Q: About Re-Tain contract manufacturer inspection process, A: No update on delay or acceleration, but confident contract manufacturer is working to resolve inspectional observations.